These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35343063)

  • 1. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes.
    Shanker MD; Garimall S; Gatt N; Foley H; Crowley S; Le Cornu E; Muscat K; Soon W; Atkinson V; Xu W; Watkins T; Huo M; Foote MC; Pinkham MB
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):536-545. PubMed ID: 35343063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2020 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases.
    Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long duration of immunotherapy before radiosurgery might improve intracranial control of melanoma brain metastases.
    Fenioux C; Troussier I; Amelot A; Borius PY; Canova CH; Blais E; Mazeron JJ; Maingon P; Valéry CA
    Cancer Radiother; 2023 May; 27(3):206-213. PubMed ID: 37149466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
    Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
    Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
    J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases.
    El Shafie RA; Celik A; Weber D; Schmitt D; Lang K; König L; Bernhardt D; Höne S; Forster T; von Nettelbladt B; Adeberg S; Debus J; Rieken S
    J Neurooncol; 2020 May; 147(3):607-618. PubMed ID: 32239433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA.
    Kessel KA; Deichl A; Gempt J; Meyer B; Posch C; Diehl C; Zimmer C; Combs SE
    Clin Transl Oncol; 2021 Oct; 23(10):2020-2029. PubMed ID: 33993415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
    Zubatkina I; Ivanov P
    J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.